131 related articles for article (PubMed ID: 38632023)
1. Epidemiology and antimicrobial susceptibility profiles of Enterobacterales causing bloodstream infections before and during COVID-19 pandemic: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2018-2021.
Lee YL; Liu CE; Tang HJ; Huang YT; Chen YS; Hsueh PR;
J Microbiol Immunol Infect; 2024 Jun; 57(3):446-456. PubMed ID: 38632023
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
Chang CY; Lee YL; Huang YT; Ko WC; Ho MW; Hsueh PR
Int J Antimicrob Agents; 2023 Jun; 61(6):106815. PubMed ID: 37059343
[TBL] [Abstract][Full Text] [Related]
3. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
4. Imipenem-Relebactam Susceptibility in
Hernández-García M; García-Castillo M; Bou G; Cercenado E; Delgado-Valverde M; Oliver A; Pitart C; Rodríguez-Lozano J; Tormo N; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Cruz H; Chaves C; Duarte J; Pássaro L; Díaz-Regañón J; Cantón R
Microbiol Spectr; 2022 Oct; 10(5):e0292722. PubMed ID: 36043877
[TBL] [Abstract][Full Text] [Related]
5. Geographical distribution of Enterobacterales with a carbapenemase IMP-6 phenotype and its association with antimicrobial use: An analysis using comprehensive national surveillance data on antimicrobial resistance.
Hirabayashi A; Yahara K; Kajihara T; Sugai M; Shibayama K
PLoS One; 2020; 15(12):e0243630. PubMed ID: 33332370
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of multidrug-resistant Enterobacterales carrying extended-spectrum beta-lactamase and AmpC genes isolated from neonatal sepsis in Ahvaz, Iran.
Mansouri S; Savari M; Malakian A; Abbasi Montazeri E
BMC Microbiol; 2024 Apr; 24(1):136. PubMed ID: 38658819
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
Lee YL; Chen YS; Toh HS; Huang CC; Liu YM; Ho CM; Lu PL; Ko WC; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Liu CE; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S29-36. PubMed ID: 22749056
[TBL] [Abstract][Full Text] [Related]
8. Pathogen Prevalence and Antimicrobial Susceptibility Among Enterobacteriaceae Causing Hospital-associated Intra-abdominal Infections in Adults in the United States (2012-2013).
Zalacain M; Biedenbach DJ; Badal RE; Young K; Motyl M; Sahm DF
Clin Ther; 2016 Jun; 38(6):1510-1521. PubMed ID: 27234360
[TBL] [Abstract][Full Text] [Related]
9. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
10.
Stewart AG; Cottrell K; Henderson A; Vemuri K; Bauer MJ; Paterson DL; Harris PNA
Microbiol Spectr; 2021 Sep; 9(1):e0022621. PubMed ID: 34232101
[TBL] [Abstract][Full Text] [Related]
11. Non-susceptibilities to antibiotics against important Gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible Enterobacterales and Pseudomonas aeruginosa isolates implicated in complicated intra-abdominal and urinary tract infections in Taiwan, 2019.
Jean SS; Lu MC; Ho MW; Ko WC; Hsueh PR;
Int J Antimicrob Agents; 2022 Mar; 59(3):106521. PubMed ID: 35066144
[TBL] [Abstract][Full Text] [Related]
12. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
[TBL] [Abstract][Full Text] [Related]
13. Influence of Antimicrobial Stewardship and Molecular Rapid Diagnostic Tests on Antimicrobial Prescribing for Extended-Spectrum Beta-Lactamase- and Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae in Bloodstream Infection.
Kunz Coyne AJ; Casapao AM; Isache C; Morales J; McCarter YS; Jankowski CA
Microbiol Spectr; 2021 Oct; 9(2):e0046421. PubMed ID: 34704795
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
15. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
Lee YL; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2022; 60(5-6):106679. PubMed ID: 36241011
[TBL] [Abstract][Full Text] [Related]
16. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
Shortridge D; Kantro V; Castanheira M
Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
[TBL] [Abstract][Full Text] [Related]
17. Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
Hernández-García M; García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Costa E; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva T; Chaves C; Pássaro L; Paixão L; Romano J; Cantón R;
Int J Antimicrob Agents; 2021 Feb; 57(2):106259. PubMed ID: 33310115
[TBL] [Abstract][Full Text] [Related]
18. Distribution of β-lactamases and emergence of carbapenemases co-occurring Enterobacterales isolates with high-level antibiotic resistance identified from patients with intra-abdominal infection in the Asia-Pacific region, 2015-2018.
Chen YC; Chen WY; Hsu WY; Tang HJ; Chou Y; Chang YH; Chen CC; Chuang YC; Chang TH
J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1263-1272. PubMed ID: 34330663
[TBL] [Abstract][Full Text] [Related]
19. Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan.
Yang TY; Hsieh YJ; Kao LT; Liu GH; Lian SH; Wang LC; Lin IL; Wang HY; Tseng SP; Lu PL
J Microbiol Immunol Infect; 2022 Feb; 55(1):86-94. PubMed ID: 33678555
[TBL] [Abstract][Full Text] [Related]
20. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL
Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
